OTCMKTS:SGIOF

Shionogi & Co., Ltd. (SGIOF) Stock Price, News & Analysis

$49.60
0.00 (0.00%)
(As of 04/25/2024 ET)
Today's Range
$49.60
$49.60
50-Day Range
$46.96
$53.50
52-Week Range
$40.46
$53.50
Volume
N/A
Average Volume
550 shs
Market Capitalization
N/A
P/E Ratio
0.55
Dividend Yield
38.51%
Price Target
N/A
SGIOF stock logo

About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOF)

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

SGIOF Stock Price History

SGIOF Stock News Headlines

“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
See More Headlines
Receive SGIOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:SGIOF
Fax
N/A
Employees
5,680
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Isao Teshirogi Ph.D. (Age 65)
    CEO, President & Representative Director
    Comp: $1.9M
  • Susumu Mitsumori
    Vice President of Finance & Accounting Department
  • Mr. Kazuhiro Hatanaka
    Senior Executive Officer & Senior VP of Administration Division
  • Mr. Takeshi Shiota Ph.D.
    Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.
  • Mr. Yoshimasa Kyokawa
    Vice President of Corporate Communications & Secretary Office
  • Yoshihiro Furuya
    Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office
  • Mr. Kohji Hanasaki Ph.D.
    Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business Division
  • Dr. John A. Keller Ph.D. (Age 59)
    Senior Executive Officer and Senior VP of R&D Supervisory Unit
  • Akira Kato Ph.D.
    Corporate Officer & President of Shionogi Pharma Co., Ltd
  • Dr. Ryuichi Kiyama Ph.D.
    Senior Executive Officer & Senior VP of Corporate Strategy Division

SGIOF Stock Analysis - Frequently Asked Questions

How have SGIOF shares performed in 2024?

Shionogi & Co., Ltd.'s stock was trading at $46.21 at the beginning of 2024. Since then, SGIOF shares have increased by 7.3% and is now trading at $49.60.
View the best growth stocks for 2024 here
.

Are investors shorting Shionogi & Co., Ltd.?

Shionogi & Co., Ltd. saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 383,800 shares, a decline of 16.5% from the March 15th total of 459,700 shares. Based on an average trading volume of 300 shares, the short-interest ratio is presently 1,279.3 days.
View Shionogi & Co., Ltd.'s Short Interest
.

Is Shionogi & Co., Ltd. a good dividend stock?

Shionogi & Co., Ltd. (OTCMKTS:SGIOF) pays an annual dividend of $19.10 per share and currently has a dividend yield of 1.14%. The dividend payout ratio is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SGIOF) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners